Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Cboe UK GBp

Indivior PLC (INDVL.XC)

861.25
-7.50
(-0.86%)
At close: 4:29:51 PM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.
NameTitlePayExercisedYear Born
Mr. Mark Crossley CEO & Executive Director 1.76M -- 1970
Mr. Ryan Preblick Chief Financial Officer 856.71k -- 1976
Mr. Vishal Kalia Chief Strategy & Operating Officer -- -- 1981
Dr. Christian Heidbreder Chief Scientific Officer -- -- 1963
Mr. Jason Thompson Vice President of Investor Relations -- -- --
Ms. Cynthia Cetani Chief Integrity & Compliance Officer -- -- 1966
Mr. Jeffrey W. Burris J.D. Chief Legal Officer -- -- 1972
Ms. Angela Colon-Mahoney M.S. Chief Human Resources Officer -- -- 1976
Mr. Richard Simkin Chief Commercial Officer -- -- 1971
Mr. Hillel West Chief Manufacturing & Supply Officer -- -- 1968

Indivior PLC

10710 Midlothian Turnpike
Suite 125
North Chesterfield, VA 23235
United States
804 379 1090 https://www.indivior.com
Sector: 
Healthcare
Full Time Employees: 
1,030

Description

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Corporate Governance

Indivior PLC’s ISS Governance QualityScore as of April 1, 2025 is 4. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 1; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 24, 2025 at 6:00 AM UTC

Indivior PLC Earnings Date

Recent Events

June 16, 2016 at 12:00 AM UTC

Ex-Dividend Date